-
Views
-
Cite
Cite
News and Reviews, The Journal of Clinical Endocrinology & Metabolism, Volume 97, Issue 8, 1 August 2012, Pages A29–A30, https://doi.org/10.1210/jcem.97.8.zega29
- Share Icon Share
Extract
THE U.S. FOOD AND DRUG ADMINISTRATION approved Belviq (lorcaserin hydrochloride), as an addition to a reduced-calorie diet and exercise, for adults with a body mass index (BMI) of 30 or greater (obese) or adults with a BMI of 27 or greater (overweight) with at least one weight-related comorbid condition such as hypertension, type 2 diabetes, or high cholesterol. The last weight loss drug to be approved by the agency was Xenical (orlistat) in 1999.
(http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm)
LOW BONE MASS WAS FOUND IN HIV-INFECTED young men on antiretroviral therapy, particularly those on regimens that included a protease inhibitor.
(Clin Infect Dis [August 1, 2012] 55:461)
DAILY SUPPLEMENTATION WITH N–3 FATTY ACIDS did not reduce the rate of death from cardiovascular causes in patients with dysglycemia and a high risk for cardiovascular events.
(N Engl J Med [published online June 11, 2012])
A COMBINED THERAPY OF METFORMIN AND ROSIGLITAZONE, compared to metformin alone or lifestyle intervention, helped maintain the best glycemic control in children and adolescents with type 2 diabetes.